SPOTLIGHT -
NRG/RTOG 1112 Trial Highlights Benefit of Adding SBRT to Sorafenib in Locally Advanced HCC
Acuna Discusses US Liver Cancer Incidence in Individuals of Mexican Descent
Neoadjuvant Chemo Reduces 2-Year Risk for Residual, Recurrent Disease by 28% in Colon Cancer
FDA Approval Insights: Futibatinib in FGFR2-Positive Cholangiocarcinoma
PhD Candidate Discovers Increasing Risk for Liver Cancer Among US Residents of Mexican Descent
Pembrolizumab Plus Standard Chemotherapy Improves OS in Biliary Tract Cancer
Second-Line Treatment of R/R LBCL With Lisocabtagene Maraleucel (Liso-cel)
ZUMA-7: Axicabtagene Ciloleucel as a Second-Line Therapy for LBCL
Currently Available Treatment Options for Patients With R/R DLBCL
Overview of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)
